Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase

Science Translational Medicine

Volumn 6, Issue 266, 2014, Pages

  Liu, Yan ^a,b   Asnani, Aarti ^a,b   Zou, Lin ^a   Bentley, Victoria L ^c   Yu, Min ^a   Wang, You ^a,b   Dellaire, Graham ^c   Sarkar, Kumar S ^a,b   Dai, Matthew ^a   Chen, Howard H ^a   Sosnovik, David E ^a   Shin, Jordan T ^a   Haber, Daniel A ^a,d   Berman, Jason N ^c,e   Chao, Wei ^a   Peterson, Randall T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBANILAMIDE DERIVATIVE; DIPHENYLUREA; DOXORUBICIN; IODINE; MALATE DEHYDROGENASE; MEBENDAZOLE; MITOCHONDRIAL ENZYME; THYROXINE; UNCLASSIFIED DRUG; VISNAGIN; ANTINEOPLASTIC AGENT; CARBANILIDE DERIVATIVE; CARDIOTONIC AGENT; KHELLIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL CULTURE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; EMBRYO; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PERFORMANCE; HEART PROTECTION; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR CELL CULTURE; TUMOR XENOGRAFT; ZEBRA FISH; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CARDIOMYOPATHIES; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; HEART; HUMAN; MALE; METABOLISM; MITOCHONDRION; MUSCLE CONTRACTION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBANILIDES; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; HEART; HUMANS; KHELLIN; MALATE DEHYDROGENASE; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MUSCLE CONTRACTION; MYOCYTES, CARDIAC; NEOPLASM TRANSPLANTATION; ZEBRAFISH;

EID: 84916912350     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3010189     Document Type: Article

References (43)

1. T. M. Suter, M. S. Ewer, Cancer drugs and the heart: Importance and management. Eur. Heart J. 34, 1102-1111 (2013).
2. S. E. Lipshultz, T. R. Cochran, V. I. Franco, T. L. Miller, Treatment-related cardiotoxicity in survivors of childhood cancer. Nat. Rev. Clin. Oncol. 10, 697-710 (2013).
3. B. Ky, P. Vejpongsa, E. T. Yeh, T. Force, J. J. Moslehi, Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ. Res. 113, 754-764 (2013).
4. Y. Octavia, C. G. Tocchetti, K. L. Gabrielson, S. Janssens, H. J. Crijns, A. L. Moens, Doxorubicininduced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J. Mol. Cell. Cardiol. 52, 1213-1225 (2012).
5. C. Myers, R. Bonow, S. Palmeri, J. Jenkins, B. Corden, G. Locker, J. Doroshow, S. Epstein, A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10, 53-55 (1983).
6. S. S. Legha, Y. M. Wang, B. Mackay, M. Ewer, G. N. Hortobagyi, R. S. Benjamin, M. K. Ali, Clinical and pharmacologic investigation of the effects of a-tocopherol on adriamycin cardiotoxicity. Ann. N.Y. Acad. Sci. 393, 411-418 (1982).
7. B. B. Hasinoff, E. H. Herman, Dexrazoxane: How it works in cardiac and tumor cells. Is it a prodrug or is it a drug. Cardiovasc. Toxicol. 7, 140-144 (2007).
8. Y. Ichikawa, M. Ghanefar, M. Bayeva, R. Wu, A. Khechaduri, S. V. Naga Prasad, R. K. Mutharasan, T. J. Naik, H. Ardehali, Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J. Clin. Invest. 124, 617-630 (2014).
9. Y. L. Lyu, J. E. Kerrigan, C. P. Lin, A. M. Azarova, Y. C. Tsai, Y. Ban, L. F. Liu, Topoisomerase IIβ - mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 67, 8839-8846 (2007).
10. S. Zhang, X. Liu, T. Bawa-Khalfe, L. S. Lu, Y. L. Lyu, L. F. Liu, E. T. Yeh, Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
11. S. M. Swain, F. S. Whaley, M. C. Gerber, S. Weisberg, M. York, D. Spicer, S. E. Jones, S. Wadler, A. Desai, C. Vogel, J. Speyer, A. Mittelman, S. Reddy, K. Pendergrass, E. Velez-Garcia, M. S. Ewer, J. R. Bianchine, R. A. Gams, Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15, 1318-1332 (1997).
12. C. K. Tebbi, W. B. London, D. Friedman, D. Villaluna, P. A. De Alarcon, L. S. Constine, N. P. Mendenhall, R. Sposto, A. Chauvenet, C. L. Schwartz, Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J. Clin. Oncol. 25, 493-500 (2007).
13. X. Le, E. K. Pugach, S. Hettmer, N. Y. Storer, J. Liu, A. A. Wills, A. DiBiase, E. Y. Chen, M. S. Ignatius, K. D. Poss, A. J. Wagers, D. M. Langenau, L. I. Zon, A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development. Development 140, 2354-2364 (2013).
14. R.M. White, J. Cech, S. Ratanasirintrawoot, C. Y. Lin, P. B. Rahl, C. J. Burke, E. Langdon, M. L. Tomlinson, J. Mosher, C. Kaufman, F. Chen, H. K. Long, M. Kramer, S. Datta, D. Neuberg, S. Granter, R. A. Young, S. Morrison, G. N. Wheeler, L. I. Zon, DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518-522 (2011).
15. R. T. Peterson, S. Y. Shaw, T. A. Peterson, D. J. Milan, T. P. Zhong, S. L. Schreiber, C. A. MacRae, M. C. Fishman, Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat. Biotechnol. 22, 595-599 (2004).
16. J. T. Shin, E. V. Pomerantsev, J. D. Mably, C. A. MacRae, High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish. Physiol. Genomics 42, 300-309 (2010).
17. H. H. Chen, L. Josephson, D. E. Sosnovik, Imaging of apoptosis in the heart with nanoparticle technology. Wiley interdisciplinary reviews. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 86-99 (2011).
18. A. Hiona, A. S. Lee, J. Nagendran, X. Xie, A. J. Connolly, R. C. Robbins, J. C. Wu, Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J. Thorac. Cardiovasc. Surg. 142, 396-403.e3 (2011).
19. S. Varrone, E. Consiglio, I. Covelli, The nature of inhibition of mitochondrial malate dehydrogenase by thyroxine, iodine cyanide and molecular iodine. Eur. J. Biochem. 13, 305-312 (1970).
20. P. Tejada, M. Sanchez-Moreno, M. Monteoliva, H. Gomez-Banqueri, Inhibition of malate dehydrogenase enzymes by benzimidazole anthelmintics. Vet. Parasitol. 24, 269-274 (1987).
21. B. Kaul, E. J. Staba, Visnagin: Biosynthesis and isolation from Ammi visnaga suspension cultures. Science 150, 1731-1732 (1965).
22. P. Vanachayangkul, K. Byer, S. Khan, V. Butterweck, An aqueous extract of Ammi visnaga fruits and its constituents khellin and visnagin prevent cell damage caused by oxalate in renal epithelial cells. Phytomedicine 17, 653-658 (2010).
23. M. S. Kwon, J. K. Lee, S. H. Park, Y. B. Sim, J. S. Jung, M. H. Won, S. M. Kim, H. W. Suh, Neuroprotective effect of visnagin on kainic acid-induced neuronal cell death in the mice hippocampus. Korean J. Physiol. Pharmacol. 14, 257-263 (2010).
24. J. K. Lee, J. S. Jung, S. H. Park, S. H. Park, Y. B. Sim, S. M. Kim, T. S. Ha, H. W. Suh, Antiinflammatory effect of visnagin in lipopolysaccharide-stimulated BV-2 microglial cells. Arch. Pharm. Res. 33, 1843-1850 (2010).
25. Y. Alfaro, G. Delgado, A. Cárabez, B. Anguiano, C. Aceves, Iodine and doxorubicin, a good combination for mammary cancer treatment: Antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection. Mol. Cancer 12, 45 (2013).
26. E. G. Hong, B. W. Kim, D. Y. Jung, J. H. Kim, T. Yu, W. Seixas Da Silva, R. H. Friedline, S. D. Bianco, S. P. Seslar, H. Wakimoto, C. I. Berul, K. S. Russell, K. W. Lee, P. R. Larsen, A. C. Bianco, J. K. Kim, Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. Endocrinology 154, 3937-3946 (2013).
27. S. Beeckmans, L. Kanarek, Demonstration of physical interactions between consecutive enzymes of the citric acid cycle and of the aspartate-malate shuttle. A study involving fumarase, malate dehydrogenase, citrate synthesis and aspartate aminotransferase. Eur. J. Biochem. 117, 527-535 (1981).
28. M. Kanehisa, S. Goto, KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
29. M. Kanehisa, S. Goto, Y. Sato, M. Kawashima, M. Furumichi, M. Tanabe, Data, information, knowledge and principle: Back to metabolism in KEGG. Nucleic Acids Res. 42, D199-D205 (2014).
30. S. F. Altschul, T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, D. J. Lipman, Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 25, 3389-3402 (1997).
31. T. T. Nielsen, N. B. Støttrup, B. Løfgren, H. E. Bøtker, Metabolic fingerprint of ischaemic cardioprotection: Importance of the malate-aspartate shuttle. Cardiovasc. Res. 91, 382-391 (2011).
32. O. Warburg, On respiratory impairment in cancer cells. Science 124, 269-270 (1956).
33. W. Rottbauer, G. Wessels, T. Dahme, S. Just, N. Trano, D. Hassel, C. G. Burns, H. A. Katus, M. C. Fishman, Cardiac myosin light chain-2: A novel essential component of thickmyofilament assembly and contractility of the heart. Circ. Res. 99, 323-331 (2006).
34. W. C. Claycomb, N. A. Lanson Jr., B. S. Stallworth, D. B. Egeland, J. B. Delcarpio, A. Bahinski, N. J. Izzo Jr., HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U.S.A. 95, 2979-2984 (1998).
35. P. Korge, P. Ping, J. N. Weiss, Reactive oxygen species production in energized cardiac mitochondria during hypoxia/reoxygenation: Modulation by nitric oxide. Circ. Res. 103, 873-880 (2008).
36. L. Zou, Y. Feng, Y. J. Chen, R. Si, S. Shen, Q. Zhou, F. Ichinose, M. Scherrer-Crosbie, W. Chao, Toll-like receptor 2 plays a critical role in cardiac dysfunction during polymicrobial sepsis. Crit. Care Med. 38, 1335-1342 (2010).
37. T. G. Neilan, D. S. Jassal, T. M. Perez-Sanz, M. J. Raher, A. D. Pradhan, E. S. Buys, F. Ichinose,D. B. Bayne, E. F. Halpern, A. E. Weyman, G. Derumeaux, K. D. Bloch, M. H. Picard, M. Scherrer-Crosbie, Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur. Heart J. 27, 1868-1875 (2006).
38. A. Shevchenko, M. Wilm, O. Vorm, M. Mann, Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 68, 850-858 (1996).
39. J. Peng, S. P. Gygi, Proteomics: The move to mixtures. J. Mass Spectrom. 36, 1083-1091 (2001).
40. J. K. Eng, A. L. McCormack, J. R. Yates, An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5,976-989 (1994).
41. R. M.White, A. Sessa, C. Burke, T. Bowman, J. LeBlanc, C. Ceol, C. Bourque, M. Dovey, W. Goessling, C. E. Burns, L. I. Zon, Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2, 183-189 (2008).
42. M. Haldi, C. Ton, W. L. Seng, P. McGrath, Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish. Angiogenesis 9, 139-151 (2006).
43. D. P. Corkery, G. Dellaire, J. N. Berman, Leukaemia xenotransplantation in zebrafish - Chemotherapy response assay in vivo. Br. J. Haematol. 153, 786-789 (2011).